Drug intelligence / Profile preview

sufenidone

Development stage: Phase 3
Lead developer: Guangzhou Jiayue Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

Sufenidone (SC1011) is a novel pyridone derivative under development as an oral small molecule therapy for idiopathic pulmonary fibrosis (IPF). It has demonstrated antifibrotic activity in preclinical models and is being evaluated for safety and efficacy in clinical trials. Phase 1 studies have shown that both immediate-release and modified-release formulations are well tolerated in healthy subjects, with gastrointestinal reactions being the most common adverse events. The modified-release formulation offers improved tolerability compared to the immediate-release version. Sufenidone is currently being studied in Phase 3 clinical trials for IPF[1][2][3][4][6][7].

Other names: sufenidoneSC1011SC-1011SC 1011

Beyond the preview

Go deeper on sufenidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sufenidone.

Explore the full profile